title: Myalgia during interferon therapy--does it warrant monitoring muscle enzymes?
authors.affiliation: Department of Gastroenterology, Medical Research Centre, Hamad Medical Corporation, Doha, Qatar. aniljohn44@gmail.com
authors.forename: Anil
authors.initials: A
authors.lastname: John
authors.forename: Anjum S
authors.initials: AS
authors.lastname: John
authors.forename: Kaabi Saad
authors.initials: KS
authors.lastname: Al
authors.forename: Rajvir
authors.initials: R
authors.lastname: Singh
authors.forename: Moutaz
authors.initials: M
authors.lastname: Derbala
authors.forename: Rafie
authors.initials: R
authors.lastname: Yakoub
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D003402:Creatine Kinase / Q000097:blood*; D016903:Drug Monitoring; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D009220:Myositis / Q000139:chemically induced / Q000517:prevention & control*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011446:Prospective Studies; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; C100416:peginterferon alfa-2a